In last trading session, Unicycive Therapeutics Inc (NASDAQ:UNCY) saw 1.37 million shares changing hands with its beta currently measuring 2.14. Company’s recent per share price level of $0.59 trading at $0.04 or 7.57% at ring of the bell on the day assigns it a market valuation of $70.63M. That closing price of UNCY’s stock is at a discount of -171.19% from its 52-week high price of $1.60 and is indicating a premium of 66.1% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.49 million shares which gives us an average trading volume of 1.04 million if we extend that period to 3-months.

For Unicycive Therapeutics Inc (UNCY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.

Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information

Upright in the green during last session for gaining 7.57%, in the last five days UNCY remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $0.59 price level, adding 9.23% to its value on the day. Unicycive Therapeutics Inc’s shares saw a change of -25.71% in year-to-date performance and have moved -5.81% in past 5-day. Unicycive Therapeutics Inc (NASDAQ:UNCY) showed a performance of 5.06% in past 30-days. Number of shares sold short was 1.52 million shares which calculate 1.93 days to cover the short interests.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -31.80% during past 5 years.

Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders

Insiders are in possession of 5.31% of company’s total shares while institution are holding 52.37 percent of that, with stock having share float percentage of 55.30%. Investors also watch the number of corporate investors in a company very closely, which is 52.37% institutions for Unicycive Therapeutics Inc that are currently holding shares of the company. VIVO CAPITAL, LLC is the top institutional holder at UNCY for having 3.47 million shares of worth $1.74 million. And as of 2024-06-30, it was holding 9.9395 of the company’s outstanding shares.

The second largest institutional holder is LOGOS GLOBAL MANAGEMENT LP, which was holding about 3.47 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.9389 of outstanding shares, having a total worth of $1.74 million.